Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marta Vidus Rosin"'
Autor:
Giovanni Palladini, Ute Hegenbart, Marta Vidus Rosin, Giampaolo Merlini, Christoph Kimmich, Remigio Moratti, Riccardo Albertini, Paolo Milani, Andrea Foli, Anthony D. Ho, Stefan Schönland
Publikováno v:
Blood. 124(15)
The kidney is involved in 70% of patients with immunoglobulin light-chain (AL) amyloidosis, but little is known on progression or reversibility of renal involvement, and criteria for renal response have never been validated. Newly diagnosed patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0451b8b21ccef6b393abb22b2b9aa36
https://pubmed.ncbi.nlm.nih.gov/25301329
https://pubmed.ncbi.nlm.nih.gov/25301329
Autor:
Matej Rubelli Furman, Francesca Esposito, Giuseppe Bellini, Marta Vidus Rosin, Rita Moretti, Paola Torre, Rodolfo M. Antonello
There is currently no consensus on the nosological position of apathy in clinical practice, although many different articles indicate that apathy is a common, behavioral disturbance in the general Parkinson’s disease (PD) population, often related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af17eb3f701f648e92358f8f26861005
https://journals.sagepub.com/doi/10.1177/1533317512445502
https://journals.sagepub.com/doi/10.1177/1533317512445502
Publikováno v:
Blood. 122:288-288
In the present trial (NCT01510613) we treated with the combination of pomalidomide and dexamethasone (PDex) 27 patients previously exposed to alkylators and bortezomib. All the patients were refractory to the last line of therapy performed. The media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483b7981682c200363a4e65b29ceb57c
https://doi.org/10.1182/blood.v122.21.288.288
https://doi.org/10.1182/blood.v122.21.288.288
Publikováno v:
Blood. 122:1985-1985
Two recent reports by the Mayo Clinic and UK groups showed that the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) grants a high rate of complete response (CR) and very good partial response (VGPR) in AL amyloidosis. In the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df94fc770f88f5fc61ab458f2e6118e
https://doi.org/10.1182/blood.v122.21.1985.1985
https://doi.org/10.1182/blood.v122.21.1985.1985
Publikováno v:
Blood. 122:3087-3087
A recent consensus revised the criteria for hematologic and cardiac response to treatment in AL amyloidosis based on patients’ survival. However, although the kidney is involved in approximately 70% of patients with AL amyloidosis, the criteria for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d24ef382ee7c65f74929592f019ddee
https://doi.org/10.1182/blood.v122.21.3087.3087
https://doi.org/10.1182/blood.v122.21.3087.3087